{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:37:09Z","timestamp":1773272229583,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jdiacomp.2017.01.008","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T16:33:54Z","timestamp":1485016434000},"page":"726-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes"],"prefix":"10.1016","volume":"31","author":[{"given":"Xianlong","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/157339912800840505","article-title":"FGF21: The center of a transcriptional nexus in metabolic regulation","volume":"8","author":"Adams","year":"2012","journal-title":"Current Diabetes Reviews"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2337\/db08-1470","article-title":"Targeting hepatic glucokinase in type 2 diabetes: Weighing the benefits and risks","volume":"58","author":"Agius","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2014.01.003","article-title":"Liver disease and diabetes: Association, pathophysiology, and management","volume":"104","author":"Ahmadieh","year":"2014","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12906-015-0899-6","article-title":"Anti-diabetic potential of Catharanthus roseus Linn. And its effect on the glucose transport gene (GLUT-2 and GLUT-4) in streptozotocin induced diabetic wistar rats","volume":"15","author":"Al-Shaqha","year":"2015","journal-title":"BMC Complementary and Alternative Medicine"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0025","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0030","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2004-1024","article-title":"Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease","volume":"90","author":"Angelico","year":"2005","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1507\/endocrj.47.799","article-title":"Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL\/KsJ-db\/db mice: Comparison with troglitazone","volume":"47","author":"Aoki","year":"2000","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0040","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.diabres.2011.12.015","article-title":"An overview of the pharmacokinetics, efficacy and safety of liraglutide","volume":"97","author":"Bode","year":"2012","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s001250051286","article-title":"Insulin analogues and their potential in the management of diabetes mellitus","volume":"42","author":"Bolli","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2013.06.023","article-title":"Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice","volume":"715","author":"Camacho","year":"2013","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0060","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0065","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/157339909789804396","article-title":"The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism","volume":"5","author":"Cuevas-Ramos","year":"2009","journal-title":"Current Diabetes Reviews"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0070","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.diabres.2007.09.013","article-title":"Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies","volume":"79","author":"Davies","year":"2008","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0075","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.metabol.2014.09.002","article-title":"Type 2 diabetes mellitus and fracture risk","volume":"63","author":"Dede","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0080","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jdiacomp.2007.01.001","article-title":"Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: A review of clinical studies","volume":"21","author":"Duckworth","year":"2007","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0090","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","article-title":"Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2years as monotherapy compared with glimepiride in patients with type 2 diabetes","volume":"13","author":"Garber","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0095","doi-asserted-by":"crossref","first-page":"29582","DOI":"10.1038\/srep29582","article-title":"FGF21 ameliorates the neurocontrol of blood pressure in the high fructose-drinking rats","volume":"6","author":"He","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0100","doi-asserted-by":"crossref","first-page":"e49345","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-12-0357","article-title":"Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21","volume":"167","author":"Iglesias","year":"2012","journal-title":"European Journal of Endocrinology\/European Federation of Endocrine Societies"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0110","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbrc.2010.12.021","article-title":"Effect of alogliptin, pioglitazone and glargine on pancreatic \u03b2-cells in diabetic db\/db mice","volume":"404","author":"Kawashima","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0115","first-page":"359","article-title":"FGF21: A novel prospect for the treatment of metabolic diseases","volume":"10","author":"Kharitonenkov","year":"2009","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0120","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCO.0b013e328346a326","article-title":"Fibroblast growth factor 21: Effects on carbohydrate and lipid metabolism in health and disease","volume":"14","author":"Kralisch","year":"2011","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1345\/aph.1A301","article-title":"Insulin glargine: A new basal insulin","volume":"36","author":"Levien","year":"2002","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0135","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3724\/SP.J.1206.2009.00238","article-title":"FGF-21 improves glucose uptake and glycogen synthesis of insulin-resistant liver cells","volume":"36","author":"Liu","year":"2009","journal-title":"Progress in Biochemistry and Biophysics"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.clinthera.2013.03.021","article-title":"Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8mg or twice-daily exenatide 10\u03bcg","volume":"35","author":"Malmen\u00e4s","year":"2013","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0145","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1592\/phco.29.pt2.33S","article-title":"Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog","volume":"29","author":"Meece","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/dmrr.2608","article-title":"Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL\/KsJ db\/db mice with degenerative diabetes","volume":"31","author":"Moffett","year":"2015","journal-title":"Diabetes\/Metabolism Research and Reviews"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2337\/db11-0838","article-title":"FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents","volume":"61","author":"Mu","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/dom.12012","article-title":"Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study","volume":"15","author":"Nauck","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0165","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1345\/aph.1M134","article-title":"Liraglutide: A once-daily incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"43","author":"Neumiller","year":"2009","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0170","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1262-3636(07)70133-7","article-title":"Role of the liver in the control of carbohydrate and lipid homeostasis","volume":"30","author":"Postic","year":"2004","journal-title":"Diabetes & Metabolism"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0175","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jdiacomp.2015.05.007","article-title":"Fracture risk in patients with newly diagnosed type 2 diabetes: A retrospective database analysis in primary care","volume":"29","author":"Rathmann","year":"2015","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0180","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00018-009-0003-9","article-title":"Fibroblast growth factor 21: An overview from a clinical perspective","volume":"66","author":"Ryd\u00e9n","year":"2009","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0185","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/414799a","article-title":"Insulin signalling and the regulation of glucose and lipid metabolism","volume":"414","author":"Saltiel","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0190","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.phrs.2016.09.009","article-title":"Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes","volume":"113","author":"Sharma","year":"2016","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0195","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/ph3030764","article-title":"Liraglutide therapy for type 2 diabetes: Overcoming unmet needs","volume":"3","author":"Sj\u00f6holm","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0200","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1210\/en.2012-1211","article-title":"Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys","volume":"153","author":"V\u00e9niant","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2009.45.2.1336104","article-title":"Liraglutide: A new treatment for type 2 diabetes","volume":"45","author":"Vilsboll","year":"2009","journal-title":"Drugs of Today (Barcelona, Spain)"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0210","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jdiacomp.2015.04.006","article-title":"Meaning of illness and quality of life in patients with type 2 diabetes","volume":"29","author":"Walker","year":"2015","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0215","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0149-2918(03)80156-X","article-title":"Insulin glargine: A systematic review of a long-acting insulin analogue","volume":"25","author":"Wang","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0220","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0225","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0230","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","article-title":"Fibroblast growth factor 21 as an emerging metabolic regulator: Clinical perspectives","volume":"78","author":"Woo","year":"2013","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0235","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdiacomp.2014.10.001","article-title":"Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes","volume":"29","author":"Xu","year":"2015","journal-title":"Journal of Diabetes and its Complications"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0245","first-page":"897","article-title":"Optimization and characterization of a novel FGF21 mutant","volume":"47","author":"Ye","year":"2012","journal-title":"Acta Pharmaceutica Sinica"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0250","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2174\/1389201015666140515124838","article-title":"Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation","volume":"14","author":"Ye","year":"2013","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0255","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejphar.2016.04.025","article-title":"Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity","volume":"781","author":"Ye","year":"2016","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.jdiacomp.2017.01.008_bb0260","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11010-016-2774-2","article-title":"FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy","volume":"420","author":"Zhu","year":"2016","journal-title":"Molecular and Cellular Biochemistry"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716309059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716309059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T23:23:42Z","timestamp":1536103422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716309059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1056872716309059"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.008","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}